ClinicalTrials.gg
RecruitingNCT07756957Updated Nov 18, 2026

Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne

A Phase 1/2 interventional study of Acne mRNA (messenger ribonucleic acid) vaccine and Placebo in Acne, sponsored by Sanofi. Recruiting at 3 sites in Canada. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Sanofi · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Now RecruitingFirst site in Canada+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies in Acne Vulgaris with a site in Canada — 4 open to participants now, 5 under way, none of them phase 3. Acne Vulgaris · Canada.

Planned enrollment
25th of 56
410 · median 257
Started
2026
with 1 other
Phase 1/2
5 of 59
2 open now
Registered
59th of 59
by date

Among the 59 studies in Acne Vulgaris with a site in Canada, this one is the 25th largest by planned enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 1/2, and was the 59th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

4 of the 59 studies in Acne Vulgaris with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acne Vulgaris with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety profile of intramuscular injections of the Acne mRNA vaccine at 3 dose levels compared with placebo in 12 to 17 years old participants with moderate to severe acne.

An early safety data review (ESDR) will be conducted after each subcohort has completed an injection round; enrollment of the next higher dose level subcohort or progression of a subcohort to the subsequent injection round will only proceed if no safety concerns are identified. This sequential process will allow a cautious approach to vaccine injection in the adolescent population.

Study details are as follows:

  • Before being enrolled in the study, participants complete a 4-week (ie, 1-month) screening period during which they will be called over the telephone approximately in the middle of the screening period to check they are not using prohibited medications and to remind them about the facial hygiene requirements.
  • Once the screening period has been completed, the study duration will be up to 13 months for each participant
  • Participants will be invited to a long-term extension study through a separate protocol.
03

Conditions studied

  • Acne

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 12 to 17 years on the day of the first study intervention administration
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests as judged by the investigator
  • Clinical diagnosis of moderate or severe facial acne vulgaris with Investigator's Global Assessment (IGA) score of Moderate or Severe (grade 3 or grade 4 on the 5-grade IGA scale) and ≥ 25 non-inflammatory lesions (ie, open and closed comedones) and ≥ 20 inflammatory lesions (ie, papules and pustules) and ≤ 2 nodulocystic lesions (ie, nodules and cysts)

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the first study intervention administration; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic to any study intervention components or history of life-threatening reaction to study intervention(s) or products with the same substances
  • Active nodulocystic acne, acne conglobate, acne fulminans, secondary acne (eg, chloracne, drug-induced acne) or other forms of acne (eg, acne mechanica)
  • Use of any acne-affecting treatment without an appropriate
  • Any vaccine given in the 4 weeks before or after any injection of study intervention
  • Previous vaccination against C. acnes with an vaccine
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Self-reported or documented seropositivity for (HIV), virus, or virus

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
410 participants (estimated)

Study arms

  • Experimental
    Dose 1 sub-cohort - Group 1

    3 injections

    Biological: Acne mRNA (messenger ribonucleic acid) vaccine

  • Placebo comparator
    Dose 1 sub-cohort - Group 2

    3 injections

    Biological: Placebo

  • Experimental
    Dose 2 sub-cohort - Group 3

    3 injections

    Biological: Acne mRNA (messenger ribonucleic acid) vaccine

  • Placebo comparator
    Dose 2 sub-cohort - Group 4

    3 injections

    Biological: Placebo

  • Experimental
    Dose 3 sub-cohort - Group 5

    3 injections

    Biological: Acne mRNA (messenger ribonucleic acid) vaccine

  • Placebo comparator
    Dose 3 sub-cohort - Group 6

    3 injections

    Biological: Placebo

  • Experimental
    Dose 1 main cohort - Group 7

    3 injections

    Biological: Acne mRNA (messenger ribonucleic acid) vaccine

  • Experimental
    Dose 2 main cohort - Group 8

    3 injections

    Biological: Acne mRNA (messenger ribonucleic acid) vaccine

  • Experimental
    Dose 3 main cohort - Group 9

    3 injections

    Biological: Acne mRNA (messenger ribonucleic acid) vaccine

  • Placebo comparator
    Main cohort - Group 10

    3 injections

    Biological: Placebo

Interventions

  • BiologicalAcne mRNA (messenger ribonucleic acid) vaccine

    IM injection

  • BiologicalPlacebo

    IM injection

06

What researchers measure

Primary outcomes

  1. Unsolicited systemic AEs (Adverse Events)

    Presence of unsolicited systemic adverse events (AEs) reported

    Time frame: 30 minutes after each injection

  2. Solicited injection site and systemic adverse reactions

    Presence of solicited injection site and systemic reactions (ie, pre-listed in the participant diary \[PDi\] and in the case report form \[CRF\])

    Time frame: 8 days, including the day of each injection

  3. Unsolicited AEs

    Presence of unsolicited adverse events (AEs) reported

    Time frame: 28 days, including the day of each injection

  4. SAEs (Serious Adverse Events), MAAEs (Medically Attended Adverse Event), AESIs (Adverse Event of Special Interest) and AEs (Adverse Events) leading to study discontinuation

    Presence of SAEs (Serious Adverse Events), MAAEs (Medically Attended Adverse Event), AESIs (Adverse Event of Special Interest) and AEs (Adverse Events) leading to study discontinuation

    Time frame: Up to 2 months after last injection

  5. Out-of-range biological test results (including shift from baseline values)

    Time frame: Within 8 days after each injection, including the day of injection

Secondary outcomes

  1. Percentage change from baseline in total number of acne lesions on the face

    Time frame: At 2 months after last injection

  2. SAEs (Serious Adverse Events), MAAEs (Medically Attended Adverse Event), AESIs (Adverse Event of Special Interest) and AEs (Adverse Events) leading to study discontinuation

    Presence of SAEs (Serious Adverse Events), MAAEs (Medically Attended Adverse Event), AESIs (Adverse Event of Special Interest) and AEs (Adverse Events) leading to study discontinuation

    Time frame: Up to 13 months

  3. Absolute and percentage change from baseline in the number of inflammatory acne lesions on the face

    Time frame: At 1 month after first injection until 9 months after last injection

  4. Absolute and percentage change from baseline in the number of non- inflammatory acne lesions on the face

    Time frame: At 1 month after first injection until 9 months after last injection

  5. Absolute and percentage change from baseline in total number of acne lesions on the face

    Time frame: At 1 month after first injection until 9 months after last injection

07

Study locations

3 of 3 sites recruiting
  • Investigational Site Number : 1240001
    Edmonton, Alberta T5J 3S9, Canada
    Recruiting
  • Investigational Site Number : 1240013
    Edmonton, Alberta T6w 0J5, Canada
    Recruiting
  • Investigational Site Number : 1240009
    Vancouver, British Columbia V6C 0C3, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2028, 21 months after the start.

Of 14 phase 1/2 interventional studies under Acne Vulgaris, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's planned 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2026
First posted
Aug 11, 2026
StartActual
Oct 14, 2026
Primary completionEst.
Jul 19, 2028
CompletionEst.
Feb 19, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
3 sites added — first site in Canada
Show 3 added (3 Canada)
  • Investigational Site Number : 1240001 · Edmonton, Canada
  • Investigational Site Number : 1240013 · Edmonton, Canada
  • Investigational Site Number : 1240009 · Vancouver, Canada
Nov 18, 2026
Start date
Oct 30, 2026→Oct 14, 2026 (actual)
Nov 18, 2026
Design
Added Phase 1
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    3 sites added — first site in Canada
    Show 3 added (3 Canada)
    • Investigational Site Number : 1240001 · Edmonton, Canada
    • Investigational Site Number : 1240013 · Edmonton, Canada
    • Investigational Site Number : 1240009 · Vancouver, Canada
    Start date Oct 30, 2026→Oct 14, 2026 (now actual)
    Design Added Phase 1
    + 4 other changes: verification date, registry dates, oversight details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07756957
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 11, 2026
Start date
Oct 14, 2026
Primary completion
Jul 19, 2028 (estimated)
Completion
Feb 19, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion